Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Int J Mol Sci ; 25(11)2024 May 23.
Artículo en Inglés | MEDLINE | ID: mdl-38891846

RESUMEN

Tumor recurrence and drug resistance are responsible for poor prognosis in colorectal cancer (CRC). DNA mismatch repair (MMR) deficiency or elevated interleukin-8 (IL-8) levels are characteristics of CRCs, which have been independently correlated with treatment resistance to common therapies. We recently demonstrated significantly impaired therapeutical response and increased IL-8 release of CRC cell lines with reduced expression of MMR protein MLH1 as well as cytoskeletal non-erythrocytic spectrin alpha II (SPTAN1). In the present study, decreased intratumoral MLH1 and SPTAN1 expression in CRCs could be significantly correlated with enhanced serum IL-8. Furthermore, using stably reduced SPTAN1-expressing SW480, SW620 or HT-29 cell lines, the RAS-mediated RAF/MEK/ERK pathway was analyzed. Here, a close connection between low SPTAN1 expression, increased IL-8 secretion, enhanced extracellular-signal-regulated kinase (ERK) phosphorylation and a mesenchymal phenotype were detected. The inhibition of ERK by U0126 led to a significant reduction in IL-8 secretion, and the combination therapy of U0126 with FOLFOX optimizes the response of corresponding cancer cell lines. Therefore, we hypothesize that the combination therapy of FOLFOX and U0126 may have great potential to improve drug efficacy on this subgroup of CRCs, showing decreased MLH1 and SPTAN1 accompanied with high serum IL-8 in affected patients.


Asunto(s)
Butadienos , Neoplasias Colorrectales , Fluorouracilo , Interleucina-8 , Nitrilos , Humanos , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Colorrectales/metabolismo , Neoplasias Colorrectales/patología , Neoplasias Colorrectales/genética , Interleucina-8/metabolismo , Interleucina-8/genética , Fluorouracilo/farmacología , Fluorouracilo/uso terapéutico , Butadienos/farmacología , Nitrilos/farmacología , Línea Celular Tumoral , Compuestos Organoplatinos/farmacología , Compuestos Organoplatinos/uso terapéutico , Leucovorina/uso terapéutico , Leucovorina/farmacología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Femenino , Masculino , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Células HT29 , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Homólogo 1 de la Proteína MutL/metabolismo , Homólogo 1 de la Proteína MutL/genética , Persona de Mediana Edad , Anciano , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Fosforilación/efectos de los fármacos
2.
Case Rep Neurol ; 15(1): 1-5, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36742445

RESUMEN

Diffuse midline gliomas are a new entity in the WHO Classification of Tumors of the Central Nervous System, corresponding to grade 4 gliomas. The diagnostic pathognomonic feature is the presence of a H3K27M mutation. Although mainly seen in children, cases in adults have also been reported. The symptoms are highly variable and usually dependent on the location and extent of spinal cord compression.

3.
Pathol Oncol Res ; 29: 1610707, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36798672

RESUMEN

Accurate testing for epidermal growth factor receptor (EGFR) variants is essential for informing treatment decisions in non-small cell lung cancer (NSCLC). Automated diagnostic workflows may allow more streamlined initiation of targeted treatments, where appropriate, while comprehensive variant analysis is ongoing. FACILITATE, a real-world, prospective, multicenter, European study, evaluated performance and analytical turnaround time of the Idylla™ EGFR Mutation Test compared with local reference methods. Sixteen sites obtained formalin-fixed paraffin-embedded biopsy samples with ≥ 10% neoplastic cells from patients with NSCLC. Consecutive 5 µm sections from patient samples were tested for clinically relevant NSCLC-associated EGFR variants using the Idylla™ EGFR Mutation Test and local reference methods; performance (concordance) and analytical turnaround time were compared. Between January 2019 and November 2020, 1,474 parallel analyses were conducted. Overall percentage agreement was 97.7% [n = 1,418; 95% confidence interval (CI): 96.8-98.3], positive agreement, 87.4% (n = 182; 95% CI: 81.8-91.4) and negative agreement, 99.2% (n = 1,236; 95% CI: 98.5-99.6). There were 38 (2.6%) discordant cases. Ninety percent of results were returned with an analytical turnaround time of within 1 week using the Idylla™ EGFR Mutation Test versus ∼22 days using reference methods. The Idylla™ EGFR Mutation Test performed well versus local methods and had shorter analytical turnaround time. The Idylla™ EGFR Mutation Test can thus support application of personalized medicine in NSCLC.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas , Neoplasias Pulmonares , Humanos , Carcinoma de Pulmón de Células no Pequeñas/genética , Carcinoma de Pulmón de Células no Pequeñas/patología , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/patología , Estudios Prospectivos , Reacción en Cadena en Tiempo Real de la Polimerasa/métodos , Mutación , Receptores ErbB/genética , Análisis Mutacional de ADN/métodos
4.
J Clin Oncol ; 40(32): 3750-3761, 2022 11 10.
Artículo en Inglés | MEDLINE | ID: mdl-35709415

RESUMEN

PURPOSE: High pathologic complete response (pCR) rates and comparably good survival data were seen in a phase II trial combining perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy with trastuzumab for resectable, esophagogastric adenocarcinoma (EGA). The current trial evaluates the addition of trastuzumab and pertuzumab to FLOT as perioperative treatment for human epidermal growth factor receptor 2-positive resectable EGA. METHODS: In this multicenter, randomized phase II/III trial, patients with human epidermal growth factor receptor 2-positive, resectable EGA (≥ clinical tumor 2 or clinical nodal-positive) were assigned to four pre- and postoperative cycles of either FLOT alone (arm A) or combined with trastuzumab and pertuzumab, followed by nine cycles of trastuzumab/pertuzumab (arm B). The primary end point for the phase II part was the rate of pCR. RESULTS: The trial was closed prematurely, without transition into phase III, after results of the JACOB trial were reported. Eighty-one patients were randomly assigned (A: 41/B: 40) during the phase II part. The pCR rate was significantly improved with the trastuzumab/pertuzumab treatment (A: 12%/B: 35%; P = .02). Similarly, the rate of pathologic lymph node negativity was higher with trastuzumab/pertuzumab (A: 39%/B: 68%), whereas the R0 resection rate (A: 90%/B: 93%) and surgical morbidity (A: 43%/B: 44%) were comparable. Moreover, the inhouse mortality was equal in both arms (overall 2.5%). The median disease-free survival was 26 months in arm A and not yet reached in arm B (hazard ratio, 0.58; P = .14). After a median follow-up of 22 months, the median overall survival was not yet reached (hazard ratio, 0.56; P = .24). Disease-free survival and overall survival rates at 24 months were 54% (95% CI, 38 to 71) and 77% (95% CI, 63 to 90) in arm A and 70% (95% CI, 55 to 85) and 84% (95% CI, 72 to 96) in arm B, respectively. More ≥ grade 3 adverse events were reported with trastuzumab/pertuzumab, especially diarrhea (A: 5%/B: 41%) and leukopenia (A: 13%/B: 23%). CONCLUSION: The addition of trastuzumab/pertuzumab to perioperative FLOT significantly improved pCR and nodal negativity rates at the price of higher rates of diarrhea and leukopenia.


Asunto(s)
Adenocarcinoma , Neoplasias de la Mama , Leucopenia , Neoplasias Gástricas , Humanos , Femenino , Leucovorina/uso terapéutico , Docetaxel/efectos adversos , Oxaliplatino/uso terapéutico , Neoplasias Gástricas/tratamiento farmacológico , Neoplasias Gástricas/cirugía , Neoplasias Gástricas/patología , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Receptor ErbB-2/metabolismo , Trastuzumab/efectos adversos , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/cirugía , Adenocarcinoma/patología , Fluorouracilo/efectos adversos , Leucopenia/etiología , Diarrea/etiología , Neoplasias de la Mama/tratamiento farmacológico
5.
BMC Musculoskelet Disord ; 16: 82, 2015 Apr 10.
Artículo en Inglés | MEDLINE | ID: mdl-25888096

RESUMEN

BACKGROUND: Biological augmentation of rotator cuff repair is of growing interest to improve biomechanical properties and prevent re-tearing. But intraoperative single shot growth factor application appears not sufficient to provide healing support in the physiologic growth factor expression peaks. The purpose of this study was to establish a sustained release of granulocyte-colony stimulating factor (G-CSF) from injectable vesicular phospholipid gels (VPGs) in vitro and to examine biocompatibility and influence on histology and biomechanical behavior of G-CSF loaded VPGs in a chronic supraspinatus tear rat model. METHODS: G-CSF loaded VPGs were produced by dual asymmetric centrifugation. In vitro the integrity, stability and release rate were analyzed. In vivo supraspinatus tendons of 60 rats were detached and after 3 weeks a transosseous refixation with G-CSF loaded VPGs augmentation (n = 15; control, placebo, 1 and 10 µg G-CSF/d) was performed. 6 weeks postoperatively the healing site was analyzed histologically (n = 9; H&E by modified MOVIN score/Collagen I/III) and biomechanically (n = 6). RESULTS: In vitro testing revealed stable proteins after centrifugation and a continuous G-CSF release of up to 4 weeks. Placebo VPGs showed histologically no negative side effects on the healing process. Histologically in vivo testing demonstrated significant advantages for G-CSF 1 µg/d but not for G-CSF 10 µg/d in Collagen III content (p = 0.035) and a higher Collagen I/III ratio compared to the other groups. Biomechanically G-CSF 1 µg/d revealed a significant higher load to failure ratio (p = 0.020) compared to control but no significant differences in stiffness. CONCLUSIONS: By use of VPGs a continuous growth factor release could be obtained in vitro. The in vivo results demonstrate an improvement of immunohistology and biomechanical properties with a low dose G-CSF application via VPG. The VPG itself was well tolerated and had no negative influence on the healing behavior. Due to the favorable properties (highly adhesive, injectable, biocompatible) VPGs are a very interesting option for biologic augmentation. The study may serve as basis for further research in growth factor application models.


Asunto(s)
Portadores de Fármacos , Factor Estimulante de Colonias de Granulocitos/administración & dosificación , Fosfolípidos/química , Manguito de los Rotadores/efectos de los fármacos , Traumatismos de los Tendones/tratamiento farmacológico , Cicatrización de Heridas/efectos de los fármacos , Animales , Fenómenos Biomecánicos , Química Farmacéutica , Colágeno/biosíntesis , Terapia Combinada , Preparaciones de Acción Retardada , Modelos Animales de Enfermedad , Estabilidad de Medicamentos , Geles , Cinética , Procedimientos Ortopédicos , Ratas Sprague-Dawley , Recuperación de la Función , Manguito de los Rotadores/metabolismo , Manguito de los Rotadores/fisiopatología , Manguito de los Rotadores/cirugía , Lesiones del Manguito de los Rotadores , Solubilidad , Traumatismos de los Tendones/metabolismo , Traumatismos de los Tendones/fisiopatología , Traumatismos de los Tendones/cirugía
6.
J Transl Med ; 12: 160, 2014 Jun 06.
Artículo en Inglés | MEDLINE | ID: mdl-24906218

RESUMEN

BACKGROUND: HER2 status assessment is a prerequisite for the establishment of an appropriate treatment strategy in gastric cancer. Gastric cancers are very heterogeneous and separate evaluations of gene amplification and protein expression lead to uncertainties in localizing distinct clones and are time consuming. This study evaluates the equivalence of the novel method combining both gene and protein platforms on one slide. METHODS: Immunohistochemistry (IHC) and HER2 dual-colour silver in situ hybridization (SISH) as single methods (IHC/SISH) and gene-protein platform combining both methods on one slide (gene/protein) were performed in randomly collected 100 cases of gastric adenocarcinoma. Results of IHC/SISH were compared with gene/protein staining. RESULTS: 96 of 100 samples were assessable. In the gene/protein staining, pathologists were able to assess gene amplification and consequent protein expression at the single cell level. In comparison trials, gene amplification was observed in 14.6% by both, conventional SISH and gene/protein platform (agreement 100%; Kappa-coefficient κ = 1.0). Protein expression scores by IHC were 70.8% (0), 10.4% (1+), 9.4% (2+), and 9.4% (3+). Protein expression by gene/protein method were: 70.8% (0), 11.5% (1+), 7.3% (2+) and 10.4% (3+) of patients. There were complete concordances in IHC assessment of cases with score 0 (100.0%; κ = 1). High concordances are shown in score 1+ (98.96%; κ = 0.947) and 3+ (96.88%; κ = 0.825) cases and good concordances in 2+ cases (95.83%; κ = 0.728). CONCLUSIONS: This novel combined platform has the advantage of being able to evaluate both gene and the protein status in the same cancer cell and may be of particular interest for research and patient's care. ARTICLE CATEGORY: Disease Biomarker.


Asunto(s)
Hibridación in Situ/métodos , Receptor ErbB-2/metabolismo , Neoplasias Gástricas/diagnóstico , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Plata/química , Neoplasias Gástricas/metabolismo
7.
Arch Orthop Trauma Surg ; 131(3): 429-35, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21190029

RESUMEN

BACKGROUND: The aim of the study was to develop a standardized rat model for chronic rotator cuff tears. Therefore, a time point of degenerative changes that shows comparable histological changes to the chronic tendon tears in humans had to be determined. The rat shoulder has already been described as a standardized model for investigation of the healing behavior in acute supraspinatus lesions. Little data exist about the possibility of generating a chronic rotator cuff lesion. METHODS: We performed a complete detachment of the supraspinatus tendon in 45 Sprague-Dawley rats. After an interval of 3, 6 and 9 weeks (15 rats in each group), the macroscopic and histological changes were analyzed. The histological investigation included atrophy and fatty muscle degeneration, tendon degeneration and the grade of inflammatory changes. For evaluation of tendon degeneration, a modified MOVIN-Score was used. The contralateral shoulder provided as control group. RESULTS: Macroscopically the defect showed an increasing coverage with scar tissue over time with a complete closure in 73% after 9 weeks. The 3 week group showed the highest rate of persisting defects (80%). The atrophy of the supraspinatus muscle decreased from initial slight atrophy to a nearly normal muscle status in the 9 week group. Fatty infiltration was found in three animals per group regardless of the time interval after detachment. Tendon degeneration (modified MOVIN-Score) showed no significant difference between 3 and 6 weeks (p = 0.93) whereas after 9 weeks a significant increased degeneration was found (p < 0.01). In the early phase (3 and 6 weeks), inflammatory cells could be detected more frequently. CONCLUSIONS: The results show that a chronic tear of the human rotator cuff can be imitated in the rat model with some exclusion. The rapid self-healing response in the rat and the fatty infiltration of the human muscle are the main differences. However, tendon degeneration, inflammation and muscle atrophy combined with a persisting defect at 3 weeks after detachment are comparable to the chronic tendon tears in humans. This model can serve as a basis for further research in the field of rotator cuff repair for chronic lesions.


Asunto(s)
Modelos Animales de Enfermedad , Lesiones del Manguito de los Rotadores , Manguito de los Rotadores/cirugía , Animales , Humanos , Ratas , Ratas Sprague-Dawley , Procedimientos de Cirugía Plástica , Manguito de los Rotadores/patología , Estadísticas no Paramétricas , Técnicas de Sutura , Factores de Tiempo , Cicatrización de Heridas/fisiología
8.
Sarcoma ; 2007: 26539, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17680031

RESUMEN

Purpose. The antimicrobial effect of a silver-coated tumor endoprosthesis has been proven in clinical and experimental trials. However, in the literature there are no reports concerning the effect of elementary silver on osteoblast behaviour. Therefore, the prosthetic stem was not silver-coated because of concerns regarding a possible inhibition of the osseointegration. The aim of the present study was to investigate the effect of 5-25 mg of elementary silver in comparison to Ti-6Al-4V on human osteosarcoma cell lines (HOS-58, SAOS). Methods. Cell viability was determined by measuring the MTT proliferation rate. Cell function was studied by measuring alkaline phosphatase (AP) activity and osteocalcine production. Results. In the HOS-58 cells, the AP activity was statistically significant (P < 0.05) higher at a supplement of 5-10 mg of silver than of Ti-6 Al-4V at the same doses. For both cell lines, a supplement above 10 mg of silver resulted in a reduced AP activity in comparision to the Ti-6 Al-4V group, but a statistically significant difference (P < 0.05) was observed at a dose of 25 mg for the SAOS cells only. At doses of 20-25 mg in the HOS-58 cells and 10-25 mg in the SAOS cells, the reduction of the proliferation rate by silver was statistically significant (P < 0.05) compared to the Ti-6 Al-4V supplement. Discussion. In conclusion, elementary silver exhibits no cytotoxicity at low concentrations. In contrast, it seems to be superior to Ti-6 Al-4V concerning the stimulation of osteogenic maturation at these concentrations, whereas at higher doses it causes the known cytotoxic properties.

9.
Chembiochem ; 6(5): 860-5, 2005 May.
Artículo en Inglés | MEDLINE | ID: mdl-15812864

RESUMEN

Pityriasis versicolor is the most common skin mycosis in humans worldwide. Yeasts of the genus Malassezia, particularly M. furfur, a saprophyte occurring widely on human skin, are generally regarded as the causative agents. Pityriasis versicolor is often accompanied by a long-lasting depigmentation that persists even after successful antimycotic therapy. M. furfur is able to convert tryptophan into a variety of indole alkaloids, some of them showing biological properties that correlate well with certain clinical features of pityriasis versicolor. This suggests a possible role for these compounds in the depigmentation process. We now report that human melanocytes undergo apoptosis when exposed to the crude mixture of tryptophan metabolites from M. furfur. The active compound was identified as malassezin, previously isolated by us from the same source and characterized as an agonist of the aryl hydrocarbon (Ah) receptor. The compound could, therefore, contribute to the marked depigmentation observed during the course of pityriasis versicolor.


Asunto(s)
Apoptosis/efectos de los fármacos , Indoles/farmacología , Malassezia/química , Melanocitos/citología , Melanocitos/efectos de los fármacos , Receptores de Hidrocarburo de Aril/agonistas , Caspasa 9 , Caspasas/metabolismo , Células Cultivadas , Cromatografía en Capa Delgada , Ensayo Cometa , Humanos , Indoles/química , Indoles/aislamiento & purificación , L-Lactato Deshidrogenasa/metabolismo , Melanocitos/metabolismo , Microscopía Electrónica , Estructura Molecular , Receptores de Hidrocarburo de Aril/metabolismo
10.
Urol Int ; 73(4): 365-9, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15604586

RESUMEN

We report a case of giant multilocular cystadenoma of the prostate in a 43-year-old man. This is a rare benign entity of the prostate imitating symptoms of benign prostatic hyperplasia and originates from the prostate with extensive spread into the pelvis. Histologically, prostatic glands and cysts lined by cuboid to columnar epithelial cells with basally located nuclei are characteristic. Immunohistochemical staining is positive for prostate-specific antigen in the epithelial cells. Giant multilocular prostatic cystadenoma should be taken into account in the differential diagnosis in any case of a large cystic mass originating from the prostate.


Asunto(s)
Cistoadenoma/diagnóstico , Hiperplasia Prostática/patología , Neoplasias de la Próstata/patología , Adulto , Diagnóstico Diferencial , Humanos , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...